⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16096280 | 0.74 | CYP2C9 (0.46) | — | |
| SCHEMBL3722172 | 0.68 | GABRG2 (0.35) | — | |
| SCHEMBL14590841 | 0.63 | PTGS2 (0.40) | — | |
| SCHEMBL11971170 | 0.61 | LRRK2 (0.30) | — | |
| SCHEMBL24655848 | 0.55 | CA2 (0.35) | — | |
| SCHEMBL24655840 | 0.52 | CYP2C9 (0.35) | — | |
| SCHEMBL11633170 | 0.50 | — | — | |
| SCHEMBL30711609 | 0.47 | — | — | |
| SCHEMBL13158539 | 0.47 | — | — | |
| SCHEMBL2812626 | 0.41 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015709-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | claimed |
| EP-4694980-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | Takeda Pharmaceutical Company Limited (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4397663-A4 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024214046-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-17 | — | — | WO | disclosed |
| US-20240287079-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| US-20240287079-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| US-20240287079-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| JP-2024112817-A | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2024-08-21 | — | — | JP | disclosed |
| EP-4397663-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2024-07-10 | — | — | EP | disclosed |
| EP-4397663-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2024-07-10 | — | — | EP | disclosed |
| JP-2023036007-A | 6-Aminopyrazolopyrimidine compound and pharmaceutical use thereof | 日本たばこ産業株式会社 | 2023-03-13 | — | — | JP | disclosed |
| WO-2023032987-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023032987-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023032987-A1 | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-03-09 | — | — | WO | disclosed |
| US-20200308240-A1 | Targeting Innate Immune Signaling in Neuroinflammation and Neurodegeneration | THE GENERAL HOSPITAL CORPORATION | 2020-10-01 | — | — | US | disclosed |
| US-9903855-B2 | Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2017173451-A1 | TARGETING INNATE IMMUNE SIGNALING IN NEUROINFLAMMATION AND NEURODEGENERATION | THE GENERAL HOSPITAL CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9632074-B2 | Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160146783-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | UNIV CALIFORNIA (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160015709-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |